Assessing the Potential Ability of GSK239512 to Remyelinate Brain Lesions in Relapsing Remitting Multiple Sclerosis

Registry ID

EUCTR2012-003627-38

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GlaxoSmithKline Research & Development Ltd

Start date

2012-10-25

Completion date

2014-09-12

Last update

2026-08-16

Conditions

• Relapsing Remitting Multiple Sclerosis

Summary

Estimation of the effects of GSK239512 on lesion remyelination in subjects with Relapsing Remitting Multiple Sclerosis on stable treatment with Avonex [interferon-beta1a] or Copaxone [glatiramer acetate].

Locations

• , , Czechia
• , , Spain
• , , Bulgarian Drug Agency
• , , Germany
• , , Sweden
• , , UK

Related clinical trials

• A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis
• The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
• Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
• Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

View on source registry